On January 2nd, AstraZeneca and Sanofi jointly announced the long-acting monoclonal antibody Le Weichu& Reg; Nirsevimab has been officially approved for marketing by the National Medical Products Adm ...

AstraZeneca: Leweichu has been approved in China for the prevention of respiratory syncytial virus infection in infants. AstraZeneca and Sanofi jointly announced on January 2 that the long-acting mon ...